Yukuan Feng

State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine, Tianjin Key Laboratory Of Digestive Cancer, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, 300060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma.

Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma.

Journal: Cancer biology & medicine

Published: October 17, 2025

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.

Journal: Cancer discovery

Published: September 18, 2025

GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma.

GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma.

Journal: Cancer biology & medicine

Published: July 16, 2025

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

Journal: Gut

Published: June 30, 2025

Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells.

Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 21, 2025

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Journal: Gut

Published: May 05, 2025

Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity.

Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity.

Journal: Nature communications

Published: January 23, 2025

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells.

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells.

Journal: Cell research

Published: September 17, 2024

The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.

The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.

Journal: Cancer letters

Published: September 03, 2024

Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling.

Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling.

Journal: Gut

Published: August 16, 2024

BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism.

BICC1 drives pancreatic cancer stemness and chemoresistance by facilitating tryptophan metabolism.

Journal: Science advances

Published: June 19, 2024

Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer.

Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer.

Journal: Nature communications

Published: June 12, 2024

Showing 1-12 of 34

Last Updated: 09/26/2026